Diasome Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products for patients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania.
Diasome Pharmaceuticals has raised $16.7M across 1 funding round on record, the most recent an undisclosed round of $16.7M announced in Sep 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Diasome Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Diasome Pharmaceuticals Funding Rounds
Diasome Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Diasome Pharmaceuticals Funding Compared to Other Biotechnology Startups
Diasome Pharmaceuticals' latest round of $16.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Diasome Pharmaceuticals in Biotechnology and Cleveland
Companies Similar to Diasome Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Diasome Pharmaceuticals Funding FAQs
What does Diasome Pharmaceuticals do?
Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products for patients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania.
How much funding has Diasome Pharmaceuticals raised?
Diasome Pharmaceuticals has raised $16.7M across 1 round on record. The most recent is an undisclosed round of $16.7M announced in Sep 2022.
When did Diasome Pharmaceuticals last raise funding?
Diasome Pharmaceuticals' most recent funding round on record is an undisclosed round of $16.7M, announced in Sep 2022.
Who is the CEO of Diasome Pharmaceuticals?
Robert Geho is listed as CEO at Diasome Pharmaceuticals.
Where is Diasome Pharmaceuticals headquartered?
Diasome Pharmaceuticals is based in Cleveland, Ohio, United States.
How many employees does Diasome Pharmaceuticals have?
Diasome Pharmaceuticals is in the 1-10 employee band.
How does Diasome Pharmaceuticals' funding compare to other Biotechnology startups?
Diasome Pharmaceuticals' latest round of $16.7M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Diasome Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Diasome Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.